HK1204925A1 - The use of alkaline phosphatase in the treatment of reduced renal function - Google Patents

The use of alkaline phosphatase in the treatment of reduced renal function

Info

Publication number
HK1204925A1
HK1204925A1 HK15105481.8A HK15105481A HK1204925A1 HK 1204925 A1 HK1204925 A1 HK 1204925A1 HK 15105481 A HK15105481 A HK 15105481A HK 1204925 A1 HK1204925 A1 HK 1204925A1
Authority
HK
Hong Kong
Prior art keywords
treatment
alkaline phosphatase
renal function
reduced renal
reduced
Prior art date
Application number
HK15105481.8A
Other languages
English (en)
Chinese (zh)
Inventor
魯洛夫‧彼得‧皮克斯
蘇珊娜‧海姆斯凱科
馬克溫‧保羅‧韋爾德斯
威蘭姆‧拉本
馬提‧貝爾納杜斯‧弗朗西斯庫斯‧武爾費林克
Original Assignee
Am Pharma Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Am Pharma Bv filed Critical Am Pharma Bv
Publication of HK1204925A1 publication Critical patent/HK1204925A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
HK15105481.8A 2007-01-30 2015-06-09 The use of alkaline phosphatase in the treatment of reduced renal function HK1204925A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07101437A EP1952823A1 (en) 2007-01-30 2007-01-30 The use of alkaline phosphatase in the treatment of reduced renal function

Publications (1)

Publication Number Publication Date
HK1204925A1 true HK1204925A1 (en) 2015-12-11

Family

ID=38002159

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15105481.8A HK1204925A1 (en) 2007-01-30 2015-06-09 The use of alkaline phosphatase in the treatment of reduced renal function
HK17105996.4A HK1232161A1 (zh) 2007-01-30 2017-06-16 鹼性磷酸酶在治療腎功能減退中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK17105996.4A HK1232161A1 (zh) 2007-01-30 2017-06-16 鹼性磷酸酶在治療腎功能減退中的用途

Country Status (11)

Country Link
US (1) US8586032B2 (xx)
EP (2) EP1952823A1 (xx)
JP (2) JP5580052B2 (xx)
CN (3) CN106466476A (xx)
AU (1) AU2008211829B2 (xx)
CA (1) CA2676968C (xx)
DK (1) DK2114441T3 (xx)
ES (1) ES2397293T3 (xx)
HK (2) HK1204925A1 (xx)
PL (1) PL2114441T3 (xx)
WO (1) WO2008094037A1 (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2847517A1 (en) * 2004-02-04 2005-08-18 Pharmaaware Sepsis B.V. Use of alkaline phosphatase for the detoxification of lps present at mucosal barriers
US20110142817A1 (en) * 2004-02-04 2011-06-16 Pharmaaware Sepsis B.V. Means and method for treating and/or preventing necrotizing enterocolitis
EP1952823A1 (en) 2007-01-30 2008-08-06 AM-Pharma B.V. The use of alkaline phosphatase in the treatment of reduced renal function
EP1985697A1 (en) * 2007-04-27 2008-10-29 AM-Pharma B.V. Modified phosphatases
AU2009285725A1 (en) 2008-08-29 2010-03-04 The General Hospital Corporation Methods of modulating gastrointestinal tract flora levels with alkaline phosphatase
WO2010025434A1 (en) * 2008-08-29 2010-03-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8932587B2 (en) 2010-02-12 2015-01-13 The General Hospital Corporation Methods of reducing or inhibiting toxic effects associated with a bacterial infection using alkaline phosphatase
RU2013133933A (ru) 2010-12-20 2015-01-27 Конинклейке Филипс Электроникс Н.В. Интерфейс пациента, имеющий оборачиваемое оголовье из ткани
ES2618794T3 (es) * 2011-06-08 2017-06-22 Am-Pharma B.V. El uso de fosfatasa alcalina para preservar la función renal
SG11201606060WA (en) * 2014-01-24 2016-08-30 Am Pharma Bv Chimeric alkaline phosphatase-like proteins
EP3461891B1 (en) * 2014-01-24 2020-07-01 AM-Pharma B.V. Downstream processing of an alkaline phosphatase
EP3600257B8 (en) 2017-03-21 2023-06-21 Theriva Biologics, Inc. Alkaline phosphatase formulations
EP3737750B1 (en) 2018-01-09 2024-06-05 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
EP4342534A3 (en) 2018-03-08 2024-05-22 AM-Pharma B.V. Recombinant alkaline phosphatase for use in treating sepsis-associated acute kidney injury
EP3773686B1 (en) 2018-03-20 2023-06-07 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
WO2019183208A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
CN112760305B (zh) * 2021-01-25 2022-04-29 浙江工业大学 一种栖热腔菌磷酸酶突变体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2176709A1 (en) * 1993-11-15 1995-05-26 Howard R. Higley Method of treating renal disease by administering igf-i and igfbp-3
EP1132086B1 (en) * 2000-01-31 2006-05-31 Pfizer Products Inc. Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure
CN1425766A (zh) 2001-12-19 2003-06-25 复旦大学 一种多肽——人含碱性磷酸酶活性位点的蛋白－9.24和编码这种多肽的多核苷酸
US7048914B2 (en) * 2002-12-12 2006-05-23 Zoltan Laboratories Placental alkaline phosphatase to control diabetes
CA2847517A1 (en) * 2004-02-04 2005-08-18 Pharmaaware Sepsis B.V. Use of alkaline phosphatase for the detoxification of lps present at mucosal barriers
EP1952823A1 (en) 2007-01-30 2008-08-06 AM-Pharma B.V. The use of alkaline phosphatase in the treatment of reduced renal function

Also Published As

Publication number Publication date
US8586032B2 (en) 2013-11-19
JP5580052B2 (ja) 2014-08-27
AU2008211829B2 (en) 2012-09-13
WO2008094037A1 (en) 2008-08-07
HK1232161A1 (zh) 2018-01-05
EP2114441A1 (en) 2009-11-11
CN104189896A (zh) 2014-12-10
CA2676968C (en) 2015-06-16
EP1952823A1 (en) 2008-08-06
CA2676968A1 (en) 2008-08-07
JP5734482B2 (ja) 2015-06-17
CN101678085A (zh) 2010-03-24
CN106466476A (zh) 2017-03-01
PL2114441T3 (pl) 2013-03-29
JP2010516808A (ja) 2010-05-20
AU2008211829A1 (en) 2008-08-07
DK2114441T3 (da) 2013-01-21
EP2114441B1 (en) 2012-10-17
ES2397293T3 (es) 2013-03-06
JP2014139202A (ja) 2014-07-31
US20100111923A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
HK1232161A1 (zh) 鹼性磷酸酶在治療腎功能減退中的用途
EG26985A (en) Zoned topsheet
GB0712735D0 (en) Dressing
IL211079A0 (en) Zoned topsheet
EP2049713A4 (en) TISSUE REJECTION
ZA201003237B (en) Dressing
GB0701426D0 (en) Compounds and their use
GB0700580D0 (en) Use
PL2036882T3 (pl) Związki o jonach obojnaczych i ich zastosowanie
GB0610553D0 (en) Dressing
IL202487A0 (en) Contrast agents
GB0608444D0 (en) Dialysis
GB0705923D0 (en) Dressing
GB0605107D0 (en) Use
GB0603010D0 (en) Bougie
EP2174629A4 (en) BUFFER
EP2214719A4 (en) Metallofullerene-DYE
GB0624105D0 (en) Use
GB0623196D0 (en) Dressing
GB0717543D0 (en) Bougie
GB0608402D0 (en) Thyroid treatment
GB0701096D0 (en) Use
PL380417A1 (pl) Opatrunek
AU318775S (en) Tampon
GB0713009D0 (en) Napkin